Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS
09:28am, Tuesday, 25'th Mar 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it has begun dosing patients at Yale MS Center in its multicenter Phase 2 trial evaluating intranasal foralumab, a fully human anti-CD3 monoclon
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
08:00am, Tuesday, 25'th Mar 2025
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
08:00am, Monday, 17'th Mar 2025
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
08:30am, Friday, 14'th Mar 2025
NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana submits FDA investigational new drug application
09:38am, Tuesday, 04'th Mar 2025
Tiziana Life Sciences Ltd has filed an investigational new drug application with the Food and Drug Administration for a clinical trial in Amyotrophic Lateral Sclerosis (ALS). Tiziana, which is advanc
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
08:00am, Tuesday, 04'th Mar 2025
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study reveals
10:26am, Thursday, 27'th Feb 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a groundbreaking study in Nature Neuroscience that demonstrates promising results for its nasal anti-CD3 therapy in treating tr
Traumatic brain injury is a leading cause of death and disability Currently, there is no treatment to prevent the long-term effects of traumatic brain injury Findings could translate into treating int
Tiziana Life Sciences nearing completion of long COVID study on foralumab
10:02am, Tuesday, 25'th Feb 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it expects to complete its preclinical study evaluating its nasal anti-CD3 foralumab as a potential treatment for long COVID in the second quarte
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
08:00am, Tuesday, 25'th Feb 2025
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences advances foralumab towards commercialization with key manufacturing partnership
08:52am, Friday, 21'st Feb 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced a new agreement with Renaissance Lakewood LLC to advance the development of its lead therapeutic candidate intranasal foralumab. The partnership
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
08:00am, Friday, 21'st Feb 2025
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences announces dosing of additional patients in MS Expanded Access Program
09:43am, Tuesday, 18'th Feb 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that additional patients with non-active secondary progressive multiple sclerosis (na-SPMS) have been dosed with its investigational therapy intranasa
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
08:00am, Tuesday, 18'th Feb 2025
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences says foralumab shows promise in Alzheimer's treatment
12:34pm, Tuesday, 11'th Feb 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its investigational drug, intranasal foralumab, is gaining attention for its potential to address Alzheimer's disease, a condition with limited treatment o
